SpliceBio has secured $135 million in a Series B funding round co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Ventures and existing investors. The capital will support clinical development of SB-007, the first FDA-authorized dual adeno-associated viral gene therapy targeting Stargardt disease, a debilitating inherited retinal disorder with no prior approved therapies. This investment underlines a strategic approach prioritizing long-term partnership and expertise alignment in the challenging field of gene therapy funding and development.